Cargando…

CSF levels of the BACE1 substrate NRG1 correlate with cognition in Alzheimer’s disease

BACKGROUND: The presynaptic protein neuregulin1 (NRG1) is cleaved by beta-site APP cleaving enzyme 1 (BACE1) in a similar way as amyloid precursor protein (APP) NRG1 can activate post-synaptic receptor tyrosine-protein kinase erbB4 (ErbB4) and was linked to schizophrenia. The NRG1/ErbB4 complex is n...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mouton-Liger, François, Dumurgier, Julien, Cognat, Emmanuel, Hourregue, Claire, Zetterberg, Henrik, Vanderstichele, Hugo, Vanmechelen, Eugeen, Bouaziz-Amar, Elodie, Blennow, Kaj, Hugon, Jacques, Paquet, Claire
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2020
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7372801/ https://www.ncbi.nlm.nih.gov/pubmed/32690068 http://dx.doi.org/10.1186/s13195-020-00655-w

Ejemplares similares

Plasma neuregulin 1 as a synaptic biomarker in Alzheimer’s disease: a discovery cohort study
por: Vrillon, Agathe, et al.
Publicado: (2022)

Cerebrospinal Fluid Alpha-Synuclein Improves the Differentiation between Dementia with Lewy Bodies and Alzheimer’s Disease in Clinical Practice
por: Lilamand, Matthieu, et al.
Publicado: (2022)

CSF level of β-amyloid peptide predicts mortality in Alzheimer’s disease
por: Boumenir, Adla, et al.
Publicado: (2019)

Blood-Based Kinase Assessments in Alzheimer’s Disease
por: Hugon, Jacques, et al.
Publicado: (2018)

Quantification of the trans-synaptic partners neurexin-neuroligin in CSF of neurodegenerative diseases by parallel reaction monitoring mass spectrometry
por: Camporesi, Elena, et al.
Publicado: (2022)

The pre-synaptic vesicle protein synaptotagmin is a novel biomarker for Alzheimer’s disease
por: Öhrfelt, Annika, et al.
Publicado: (2016)

PKR involvement in Alzheimer’s disease
por: Hugon, Jacques, et al.
Publicado: (2017)

Full-length and C-terminal neurogranin in Alzheimer’s disease cerebrospinal fluid analyzed by novel ultrasensitive immunoassays
por: Öhrfelt, Annika, et al.
Publicado: (2020)

Biomarker profiles of Alzheimer’s disease and dynamic of the association between cerebrospinal fluid levels of β-amyloid peptide and tau
por: Lafirdeen, Aysha S. Mohamed, et al.
Publicado: (2019)

BACE1 gene variants do not influence BACE1 activity, levels of APP or Aβ isoforms in CSF in Alzheimer's disease
por: Sjölander, Annica, et al.
Publicado: (2010)

A Pragmatic, Data-Driven Method to Determine Cutoffs for CSF Biomarkers of Alzheimer Disease Based on Validation Against PET Imaging
por: Dumurgier, Julien, et al.
Publicado: (2022)

Utility of CSF biomarkers in psychiatric disorders: a national multicentre prospective study
por: Paquet, Claire, et al.
Publicado: (2016)

Are ketogenic diets promising for Alzheimer’s disease? A translational review
por: Lilamand, Matthieu, et al.
Publicado: (2020)

Head‐to‐head comparison of clinical performance of CSF phospho‐tau T181 and T217 biomarkers for Alzheimer's disease diagnosis
por: Karikari, Thomas K., et al.
Publicado: (2020)

Clinical performance and head-to-head comparison of CSF p-tau235 with p-tau181, p-tau217 and p-tau231 in two memory clinic cohorts
por: Lantero-Rodriguez, Juan, et al.
Publicado: (2023)

Neurogranin and BACE1 in CSF as Potential Biomarkers Differentiating Depression with Cognitive Deficits from Early Alzheimer's Disease: A Pilot Study
por: Schipke, Carola G., et al.
Publicado: (2018)

Cerebrospinal Fluid PKR Level Predicts Cognitive Decline in Alzheimer’s Disease
por: Dumurgier, Julien, et al.
Publicado: (2013)

Relevance of Aβ42/40 Ratio for Detection of Alzheimer Disease Pathology in Clinical Routine: The PLM(R) Scale
por: Lehmann, Sylvain, et al.
Publicado: (2018)

No diurnal variation of classical and candidate biomarkers of Alzheimer’s disease in CSF
por: Cicognola, Claudia, et al.
Publicado: (2016)

What is the clinical impact of cerebrospinal fluid biomarkers on final diagnosis and management in patients with mild cognitive impairment in clinical practice? Results from a nation-wide prospective survey in France
por: Cognat, Emmanuel, et al.
Publicado: (2019)

Neurofilaments as Emerging Biomarkers of Neuroaxonal Damage to Differentiate Behavioral Frontotemporal Dementia from Primary Psychiatric Disorders: A Systematic Review
por: Davy, Vincent, et al.
Publicado: (2021)

Age and the association between apolipoprotein E genotype and Alzheimer disease: A cerebrospinal fluid biomarker–based case–control study
por: Saddiki, Hana, et al.
Publicado: (2020)

Pro-Apoptotic Kinase Levels in Cerebrospinal Fluid as Potential Future Biomarkers in Alzheimer’s Disease
por: Paquet, Claire, et al.
Publicado: (2015)

Potential sources of interference on Abeta immunoassays in biological samples
por: Vanderstichele, Hugo, et al.
Publicado: (2012)

Critical Steps to be Taken into Consideration Before Quantification of β-Amyloid and Tau Isoforms in Blood can be Implemented in a Clinical Environment
por: Vanderstichele, Hugo Marcel, et al.
Publicado: (2019)

PKR downregulation prevents neurodegeneration and β-amyloid production in a thiamine-deficient model
por: Mouton-Liger, F, et al.
Publicado: (2015)

Association between ATN profiles and mortality in a clinical cohort of patients with cognitive disorders
por: Régy, Mélina, et al.
Publicado: (2023)

β-Secretase1 biological markers for Alzheimer’s disease: state-of-art of validation and qualification
por: Hampel, Harald, et al.
Publicado: (2020)

Synaptic biomarkers in CSF aid in diagnosis, correlate with cognition and predict progression in MCI and Alzheimer's disease
por: Galasko, Douglas, et al.
Publicado: (2019)

Galectin-3 is elevated in CSF and is associated with Aβ deposits and tau aggregates in brain tissue in Alzheimer’s disease
por: Boza-Serrano, Antonio, et al.
Publicado: (2022)

Peripheral inflammation increases PKR activation, Tau phosphorylation and amyloid β production in wild-type mice
por: Mouton-Liger, François, et al.
Publicado: (2013)

Copper and zinc isotopic excursions in the human brain affected by Alzheimer's disease
por: Moynier, Frédéric, et al.
Publicado: (2020)

Lessons from Multicenter Studies on CSF Biomarkers for Alzheimer's Disease
por: Mattsson, Niklas, et al.
Publicado: (2010)

The Cerebrospinal Fluid Neurogranin/BACE1 Ratio is a Potential Correlate of Cognitive Decline in Alzheimer’s Disease
por: De Vos, Ann, et al.
Publicado: (2016)

BACE1 Processing of NRG1 Type III Produces a Myelin-Inducing Signal but Is Not Essential for the Stimulation of Myelination
por: Velanac, Viktorija, et al.
Publicado: (2012)

Is the clinical phenotype impact the prognosis in dementia with Lewy bodies?
por: Aveneau, Clément, et al.
Publicado: (2023)

Neuroprotective role of PKR in a model of neurodegeneration due to mild impairment of oxidative metabolism
por: Mouton-Liger, François, et al.
Publicado: (2013)

The past and the future of Alzheimer's disease CSF biomarkers—a journey toward validated biochemical tests covering the whole spectrum of molecular events
por: Blennow, Kaj, et al.
Publicado: (2015)

Diagnostic value of serum versus plasma phospho-tau for Alzheimer’s disease
por: Kac, Przemysław R., et al.
Publicado: (2022)

Neuroligin-1 in brain and CSF of neurodegenerative disorders: investigation for synaptic biomarkers
por: Camporesi, Elena, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_kfpgafba3ljdhc1t514p6bekfu